BidaskClub downgraded shares of The Medicines (NASDAQ:MDCO) from a hold rating to a sell rating in a report released on Saturday.
MDCO has been the subject of several other research reports. Zacks Investment Research downgraded The Medicines from a hold rating to a sell rating in a research note on Tuesday, December 26th. JPMorgan Chase & Co. reissued an overweight rating and set a $45.00 target price on shares of The Medicines in a research note on Wednesday, January 24th. Oppenheimer set a $50.00 target price on The Medicines and gave the stock a buy rating in a research note on Monday, March 12th. ValuEngine raised The Medicines from a sell rating to a hold rating in a research note on Sunday, December 31st. Finally, Chardan Capital reissued a buy rating and set a $85.00 target price on shares of The Medicines in a research note on Wednesday, January 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The Medicines has an average rating of Buy and an average price target of $50.00.
Shares of MDCO stock opened at $31.96 on Friday. The Medicines has a 52-week low of $24.45 and a 52-week high of $55.95. The company has a debt-to-equity ratio of 26.06, a quick ratio of 3.18 and a current ratio of 3.21. The firm has a market cap of $2,342.16, a PE ratio of -3.25 and a beta of 0.74.
In other news, Director William Crouse sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 21st. The stock was sold at an average price of $32.26, for a total value of $241,950.00. Following the completion of the transaction, the director now owns 60,633 shares of the company’s stock, valued at $1,956,020.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.22% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Elkfork Partners LLC acquired a new position in shares of The Medicines in the fourth quarter valued at approximately $214,000. Xact Kapitalforvaltning AB acquired a new position in shares of The Medicines in the fourth quarter valued at approximately $218,000. 683 Capital Management LLC acquired a new position in shares of The Medicines in the fourth quarter valued at approximately $1,367,000. MetLife Investment Advisors LLC acquired a new position in shares of The Medicines in the fourth quarter valued at approximately $876,000. Finally, Endurant Capital Management LP acquired a new position in shares of The Medicines in the fourth quarter valued at approximately $1,126,000.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3299042/the-medicines-mdco-lowered-to-sell-at-bidaskclub.html.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.